Key Highlights
- Viking Therapeutics reported that trial participants maintained up to 97 percent of their weight loss after switching from weekly to every-other-week dosing of VK2735.
- Patients who transitioned to monthly dosing maintained an average of 85 percent of their week-21 weight loss, compared with 61 percent among those switched to placebo.
- The weekly 17.5 milligram dose achieved 22 percent placebo-adjusted weight loss at week 33, with no plateau observed in the treatment effect.
- Viking shares rose roughly 24 percent following the announcement, and the company plans to evaluate oral maintenance dosing in a follow-on study.
Strong Results From the Maintenance Phase
Viking Therapeutics (NASDAQ:VKTX) reported Tuesday that participants in a clinical trial maintained up to 90 percent of their weight loss after switching from weekly to once-monthly injections of its experimental obesity drug VK2735, and up to 97 percent when switching to every-other-week dosing instead. The San Diego-based company said the 12-week maintenance phase followed a 21-week induction period during which participants received weekly subcutaneous doses of the drug.
Patients who transitioned to monthly dosing maintained an average of 85 percent of their week-21 weight loss across combined treatment groups, compared with 61 percent among those switched to placebo. Those who moved to every-other-week dosing maintained an average of 90 percent across combined groups, also well above the 61 percent figure recorded for the placebo group.
A Dual-Mechanism Drug With No Observed Plateau
VK2735 is a dual agonist of the GLP-1 and GIP receptors, the same underlying mechanism used by Eli Lilly's tirzepatide, sold as Zepbound for obesity and Mounjaro for type 2 diabetes. In an exploratory cohort receiving the drug's 17.5 milligram weekly dose, the trial reported 22 percent placebo-adjusted weight loss by week 33, with the company noting no clear plateau in the treatment effect through that point in the study.
Viking said the maintenance dosing regimens demonstrated excellent tolerability, with gastrointestinal adverse event rates similar to those observed in the placebo group, a finding the company highlighted as supportive of the drug's potential for long-term, adherence-friendly obesity treatment.
Shares Rise as Company Eyes Oral Formulation
Viking Therapeutics shares rose roughly 24 percent by Tuesday morning following the announcement. The company is currently running Phase 3 trials of VK2735 and is separately developing an oral formulation of the drug, and it said it plans to evaluate oral maintenance dosing regimens in a follow-on study, extending the current data beyond the subcutaneous formulation tested in this particular trial.
Outlook
Results from the planned follow-on study evaluating oral maintenance dosing, alongside continued Phase 3 progress, will likely be closely watched as key milestones for VK2735's path toward potential approval.






Please wait processing your request...